Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.
Overview
David C. Habiger, a Director at Boston Scientific Corporation (NYSE:BSX), purchased 2,100 shares of Common Stock on August 5, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($47.59); post-transaction value based on August 5, 2026 market close ($47.74).
Details
Boston Scientific Corporation is a global leader in medical technology with approximately 59,000 employees and a market capitalization of $73 billion. The company maintains a diversified product portfolio across three strategic business segments, positioning itself as a comprehensive provider of innovative medical devices for interventional procedures. With trailing twelve month (TTM) revenues of $21 billion and net income of $3.7 billion, Boston Scientific demonstrates significant scale and profitability within the medical device sector, supported by its commitment to advancing therapeutic solutions across multiple clinical specialties.
Source
Originally published at www.fool.com.